Promising skin cancer combo study halted early

NCT ID NCT03901573

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded to or had stopped responding to standard treatments. The study was stopped early, but the results may still provide useful information for future cancer therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44106, United States

  • Dana Farber

    Boston, Massachusetts, 02215, United States

  • MGH

    Boston, Massachusetts, 02215, United States

  • Mt Sinai

    New York, New York, 10029, United States

  • Northwestern University

    Chicago, Illinois, 60208, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.